The survival benefit seen with Sunitinib is a major step in the right direction when it comes to treatment of renal cell carcinoma. The median overall survival was 26.4 months for sunitinib-treated patients compared with 21.8 months for IFN-α recipients (P=0.051) and objective response rate was 47% for sunitinib compared with 12% for IFN-alpha (P < .001). This should encourage more patients and convince more treating Oncologists to consider Sutent (Sunitinib) as first line treatment of metastatic Renal Cell Cancer.
Author: RR
Oncoprescribe Blog Pemetrexed (Alimta) Maintenance
The survival benefit with the use of Pemetrexed (Alimta) Maintenance is intriguing and maybe more relevant for patients with non-squamous cell histology.
Pemetrexed (Alimta®) was given as maintenance treatment following four cycles of induction with platinum based combination chemotherapy (without Pemetrexed). Pemetrexed maintenance resulted in improvement in progression free survival as well as overall survival, but these benefits were observed only in patients with non squamous histology.
Oncoprescribe Blog Avastin for Kidney Cancer
There is now a drug that we’re very familiar with (AVASTIN) which is now available for Kidney Cancer. That gives us another option – besides the oral alternatives. One of these new regimens is Avastin plus Interferon
https://www.oncoprescribe.net/app/regimensummary.php